Últimas noticias sobre Yunhong Green CTI (NASDAQ:YHGJ) Bolsa

Yunhong Green CTI

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

Yunhong Green CTI Ltd

Trading Ideas

VLCN

Volcon Shares Halted On Circuit Breaker To The Upside, Stock Now Up 131.1%

Wells Fargo analyst Sam Reid maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Equal-Weight and lowers the price target from $135 to $130.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Mohawk Industries, Lowers Price Target to $130

Macro Economic Events

Economics

Trump Is Expected To Sign An Executive Order On Tuesday Restoring "Maximum Pressure" On Iran; Trump's Order On Iran Is Aimed At Denying Iran All Paths To A Nuclear Weapon And Countering Iran's "Malign Influence"

Wells Fargo analyst Sam Reid maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Equal-Weight and lowers the price target from $85 to $82.

Wells Fargo Maintains Equal-Weight on Masco, Lowers Price Target to $82

iShares MSCI Israel Capped Investable Market Index Fund

Senior U.S. Administration Official Says Trump Believes It Will Take 10-15 Years To Rebuild Gaza; This Is Not Something U.S. Going To Solve Alone; Trump, Israel's Netanyahu Will Discuss Second Phase Of Talks On Gaza Ceasefire And Hostage Release Deal

Benchmark analyst Daniel Kurnos maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $215 to $265.

AMZN

Benchmark Maintains Buy on Amazon.com, Raises Price Target to $265

Wells Fargo analyst Sam Reid maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $215 to $205.

FERG

Wells Fargo Maintains Overweight on Ferguson Enterprises, Lowers Price Target to $205

Wells Fargo analyst Sam Reid maintains Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) with a Overweight and raises the price target from $62 to $65.

Wells Fargo Maintains Overweight on Core & Main, Raises Price Target to $65

Wells Fargo analyst Matthew Akers maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Equal-Weight and raises the price target from $193 to $205.

Wells Fargo Maintains Equal-Weight on Woodward, Raises Price Target to $205

Rumors

TEAM

Watching Atlassian; Hearing Traders Circulate Investor Business Daily SwingTrader Buys Stock

Wells Fargo analyst Stephen Baxter maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Equal-Weight and lowers the price target from $370 to $341.

Wells Fargo Maintains Equal-Weight on Cigna, Lowers Price Target to $341

Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43456886/enterprise-reports-results-for-fourth-quarter-2024" rel="noreferrer noopener">a fourth-quarter 2024 sales</a> decline of 2.9% year over year to $14.201 billion, beating the consensus of $14.161 billion.
Adjusted EBITDA rose to $2.59 billion from $2.49 billion a year ago, and the margin expanded by 121 bps to 18.3%.
EPS was 74 cents, up from 72 cents in the fourth quarter of 2023, beating the consensus of 70 cents.
Non-GAAP Distributable Cash Flow was $2.16 billion for the quarter compared to $2.06 billion a year ago. Adjusted cash flow provided by operating activities was $2.301 billion compared to $2.215 billion a year ago.
Adjusted total gross operating margin expanded by 108 bps to 18.5%. The NGL Pipelines &amp; Services segment&#8217;s gross operating margin increased by 12% YoY to a record $1.5 billion.
Natural Gas Pipelines &amp; Services&#8217; gross margin rose 13% to $323 million, with record transportation volumes of 19.9 TBtus/d, up 5% YoY.
Petrochemical &amp; Refined Products Q4 2024 gross margin fell to $348M from $439M in Q4 2023. Pipeline volumes rose to 947 MBPD from 899 MBPD, while marine terminal volumes dropped to 296 MBPD from 352 MBPD.
Total 2024 capital investments reached $5.5 billion, including $3.9 billion for growth projects, $949 million for Pinon Midstream acquisition, and $667 million for sustaining expenses.
As of Dec. 31, 2024, total debt was $32.2 billion, including $2.3 billion in junior subordinated notes. Consolidated liquidity stood at ~$4.8 billion, combining available credit facility capacity and unrestricted cash.
In the fourth quarter of 2024, the company repurchased approximately 2.1 million of its common units on the open market for $63 million.
2025 Outlook: Organic growth investments are projected at $4.0–$4.5 billion in 2025, with sustaining expenditures estimated at $525 million.
&#8220;We currently have approximately $7.6 billion of major growth capital projects under construction. These projects will go into service over the next three years. Substantially all of these projects are related to our natural gas and NGL businesses serving the Permian Basin and related expansions to our downstream infrastructure to support growing domestic and international demand,&#8221; said A. J. &#8220;Jim&#8221; Teague, co-chief executive officer of Enterprise&#8217;s general partner.
&#8220;These projects are supported by long-term contracts and provide visibility to continuing net income and cash flow per unit growth,&#8221; commented A. J. &#8220;Jim&#8221; Teague, co-chief executive officer of Enterprise&#8217;s general partner,&#8221; he added.
&#8220;In 2025, $6 billion of major organic growth projects are expected to be completed and begin generating cash flow. These include two natural gas processing plants in the Permian Basin, our Bahia NGL pipeline, Fractionator 14, the first phase of our NGL export facility on the Neches River and expansions of our ethane and ethylene marine terminals on the Houston Ship Channel. This growth in cash flow will support future distribution increases and returns of capital,&#8221; Teague noted.
Price Action: EPD shares were down 2.1% at $32.54 during early trading Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43462165/china-strikes-retaliatory-measures-against-us-following-trumps-10-tariffs-its-much-less-than-proportional-analyst-says">China Strikes Retaliatory Measures Against US Following Trump&#8217;s 10% Tariffs: It&#8217;s &#8216;Much-Less Than Proportional,&#8217; Analyst Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Guidance

Enterprise Products Beats Q4 Forecasts, Targets $6 Billion In 2025 Expansions

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Equal-Weight and raises the price target from $135 to $136.

Wells Fargo Maintains Equal-Weight on Cardinal Health, Raises Price Target to $136

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) <a target="_blank" href="https://www.benzinga.com/topic/spotify" rel="noreferrer noopener">stock gained Tuesday</a> after the company reported better-than-expected fiscal fourth-quarter 2024 financial results. Here&#8217;s a look at the key figures <a target="_blank" href="https://investors.spotify.com/home/default.aspx" rel="noreferrer noopener">from the quarter</a>.&nbsp;&nbsp;
The Details:&nbsp;Spotify reported quarterly earnings of $1.88 per share, which missed the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.06</a>.
The company reported quarterly sales of $4.53 billion (4.24 billion euros), up by 16% year-on-year, which beat the analyst consensus estimate of $4.15 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/43432143/taiwan-semiconductor-plans-massive-1nm-fab-25-in-taiwan-boosting-advanced-chipmaking-capacity" rel="noreferrer noopener">Taiwan Semiconductor Plans Massive 1nm Fab 25 in Taiwan, Boosting Advanced Chipmaking Capacity</a>
The company reported monthly average user (MAU) net additions of 35 million quarter-over-quarter, surpassing guidance by ten million, and subscriber net additions of 11 million, also ahead by three million.
Premium subscribers grew 11% year-over-year to 263 million, reflecting year-over-year and quarter-over-quarter growth across all regions, beating expectations by $3 million.
Within Premium, the average revenue per user (ARPU) rose by 5% year over year to 4.85 euros, and ad-supported revenue rose 7%.
Margins: The gross margin improved by 555 bps to 32.2%, driven by improvements in its Premium and Ad-Supported segments.
The Premium gross margin was 34.7%, up 565 bps&nbsp;year over year, driven by favorability from audiobooks, music, and Other Costs of Revenue.&nbsp;
The ad-supported gross margin was 15.1%, up 351 bps year over year. This was driven by favorability from music, Other Cost of Revenue, and podcasts, partially offset by real estate impairment activity.
Operating income improved to 477 million euros with a margin of 11.2%.
Spotify held 7.5 billion euros in cash and equivalents, generating €877 million in free cash flow.
Outlook: Spotify expects fiscal first-quarter 2025 revenue of $4.48 billion (4.2 billion euros) versus&nbsp;a <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $4.17 billion</a> and total MAUs of 678 million.&nbsp;
Spotify paid $10 billion to the <a target="_blank" href="https://www.benzinga.com/25/01/43286514/spotify-hits-milestone-10-billion-paid-to-music-industry-in-2024-60-billion-since-founding" rel="noreferrer noopener">music industry in 2024</a>, contributing ~$60 billion since its founding. The premium subscribers rose to 252 million.
In January 2025, at least five Wall Street firms, including Goldman Sachs, Keybanc, UBS, and Macquarie, <a target="_blank" href="https://www.benzinga.com/quote/SPOT/analyst-ratings" rel="noreferrer noopener">raised their price targets</a> on Spotify.
Spotify Technology stock surged 146% in the last 12 months.
Price action:&nbsp;SPOT stock traded higher by 7.41% at $588.30 at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43431559/amazon-temu-and-shein-under-eu-scrutiny-regulators-target-illegal-products-and-tougher-e-commerce-rules" target="_blank" rel="noreferrer noopener">Amazon, Temu, and Shein Under EU Scrutiny, Regulators Target Illegal Products and Tougher E-Commerce Rules</a></li>
</ul>
Photo via Shutterstock

Eurozone

Movers

Tech

SPOT

Spotify Q4 Earnings: Revenue Beat, Higher ARPU and Premium Growth Drive Profitability, Issues Strong Q1 Outlook

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are trading higher Tuesday after the company reported better-than-expected financial results for the fourth quarter and issued strong guidance. Several analysts also lifted price targets <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-th">following the print</a>.
<ul>
<li>Q4 Revenue: $827.52 million, versus <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $775.91 million</li>
</ul>
<ul>
<li>Q4 EPS: 14 cents, versus estimates of 11 cents</li>
</ul>
Total revenue grew 36% year-over-year, driven by strong U.S. revenue growth of 52% year-over-year. U.S. Commercial revenue increased 64% year-over-year to $214 million and U.S. Government revenue was up 45% year-over-year to $343 million.
Palantir's customer count grew 43% year-over-year and 13% on a quarter-over-quarter basis. The company said it closed 129 deals worth over $1 million during the quarter and 58 deals worth at least $5 million.
Palantir generated $460 million in cash from operations and $517 million in adjusted free cash flow in the quarter.&nbsp;The company ended the quarter with $5.2 billion of cash, equivalents and short-term U.S. treasury securities.
"We are still in the earliest stages, the beginning of the first act, of a revolution that will play out over years and decades," Palantir CEO Alex Karp said in a letter to shareholders.&nbsp;
"This is not an incremental advance or marginal acceleration of our business. This is a new phase. And the momentum we are seeing across sectors, both commercial and government, is unlike anything that has come before."
See Also: <a href="https://www.benzinga.com/markets/equities/25/02/43454250/palantir-is-making-america-more-lethal-as-alex-karp-led-company-secures-1-8-billion-in-ai-contracts-us-commercial-customer-base-surges-73">Palantir Is &#8216;Making America More Lethal&#8217; As Alex Karp-Led Company Secures $1.8 Billion in AI Contracts — US Commercial Customer Base Surges 73%</a>
Outlook:&nbsp;Palantir expects first-quarter revenue to be in the range of $858 million to $862 million, versus estimates of $799.35 million. The company expects full-year 2025 revenue to be between $3.74 billion and $3.76 billion versus estimates of $3.52 billion.&nbsp;
Palantir also guided for positive GAAP operating income and net income in each quarter of 2025 and said it anticipates full-year adjusted free cash flow between $1.5 billion and $1.7 billion.
&#8220;The business we have built has now developed its own internal momentum and strength, its own interior life and forms of untamed organic growth, with the output that we are seeing far surpassing what we are investing,&#8221; Karp added.
Analyst Changes:
<ul>
<li>Jefferies analyst Brent Thill maintained an Underperform and raised the price target from&nbsp;$28&nbsp;to&nbsp;$60.</li>
</ul>
<ul>
<li>BofA Securities analyst Mariana Perez Mora maintained a Buy and raised the price target from&nbsp;$90&nbsp;to&nbsp;$125.</li>
</ul>
<ul>
<li>Morgan Stanley analyst Sanjit Singh upgraded Palantir from Underweight to Equal-Weight and raised the price target from&nbsp;$60&nbsp;to&nbsp;$95.</li>
</ul>
<ul>
<li>Mizuho analyst Matthew Broome maintained an Underperform and raised the price target from&nbsp;$44&nbsp;to&nbsp;$80.</li>
</ul>
<ul>
<li>Northland Capital Markets analyst Michael Latimore maintained a Market Perform and raised the price target from&nbsp;$38&nbsp;to&nbsp;$80.</li>
</ul>
<ul>
<li>Baird analyst William Power maintained a Neutral and raised the price target from&nbsp;$70&nbsp;to&nbsp;$100.</li>
</ul>
<ul>
<li>Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral and raised the price target from&nbsp;$72&nbsp;to&nbsp;$98.</li>
</ul>
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up 22.5% at $102.55 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

PLTR

Palantir Stock Is Surging Tuesday: What's Going On?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stephens &amp; Co. raised Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) price target from $60 to $63. Stephens &amp; Co. analyst Pooran Sharma maintained an Equal-Weight rating. Tyson shares closed at $57.74 on Monday. <a href="https://www.benzinga.com/quote/TSN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $50 to $55. Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating. Bristol-Myers Squibb shares closed at $59.95 on Monday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $262 to $285. Wells Fargo analyst Daniel Politzer maintained an Equal-Weight rating. Marriott shares closed at $290.46 on Monday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised the price target for Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) from $72 to $98. Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral rating. Palantir shares closed at $83.74 on Monday. <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Steven Madden, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) from $45 to $40. Piper Sandler analyst Anna Andreeva maintained a Neutral rating. Steven Madden shares closed at $38.32 on Monday. <a href="https://www.benzinga.com/quote/SHOO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) price target from $260 to $250. Morgan Stanley analyst Kristine Liwag maintained an Equal-Weight rating. L3Harris shares settled at $212.78 on Monday. <a href="https://www.benzinga.com/quote/LHX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised Baker Hughes Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>) price target from $51 to $55. Barclays analyst David Anderson maintained an Overweight rating. Baker Hughes shares closed at $47.40 on Monday. <a href="https://www.benzinga.com/quote/BKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) price target from $125 to $17. Baird analyst Andrew Wittmann maintained an Outperform rating. AECOM shares closed at $103.85 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) from $280 to $285. Rosenblatt analyst Mike Genovese maintained a Buy rating. Fabrinet shares settled at $225.60 on Monday. <a href="https://www.benzinga.com/quote/FN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) price target from $297 to $290. Piper Sandler analyst Aisling Grueninger maintained a Neutral rating. McDonald&#8217;s shares closed at $290.05 on Monday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

SHOO

McDonald's To $290? Here Are 10 Top Analyst Forecasts For Tuesday

<a href="https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html" title="https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html">https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html</a>

FOXA

'Fox Reveals Plans To Launch Subscription Streaming Service This Year' - CNBC

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 9.63% on an annualized basis producing an average annual return of 21.93%. Currently, Amphenol has a market capitalization of $83.03 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 5 years ago, it would be worth $2,680.34 today based on a price of $68.87 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738679410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Infineon Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) released its Q1 earnings on Tuesday, February 4, 2025 at 05:00 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Infineon Technologies beat estimated earnings by 30.0%, reporting an EPS of $0.352 versus an estimate of $0.27.
Revenue was down $330.60 million from the same period last year.
<h3>Earnings History Overview</h3>
In the previous quarter, the company beat on EPS by $0.09, resulting in a 5.0% drop change in the share price the following day.

To track all earnings releases for Infineon Technologies <a href="https://www.benzinga.com/quote/IFNNY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFNNY

Infineon Technologies Earnings Review: Q1 Summary

Quantum BioPharma Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares are rising Tuesday after the company announced positive clinical trial results for its <a href="https://www.benzinga.com/pressreleases/25/02/g43458239/quantum-biopharma-announces-the-success-of-unbuzzd-clinical-trial">unbuzzd dietary supplement</a>.
What Happened: Quantum BioPharma announced that it completed a double-blind, randomized, placebo-controlled crossover design clinical trial of unbuzzd that was aimed at investigating its effects on alcohol intoxication and alcohol metabolism.
Results showed that unbuzzed accelerated the rate at which Blood Alcohol Concentration (BAC) was reduced in study subjects, reducing symptoms of intoxication and hangover.
The rate at which BAC was lowered on average was more than 40% faster within 30 minutes of consuming unbuzzed. All results in the study were considered statistically significant compared to placebo. 
&#8220;This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover,&#8221; said Zeeshan Saeed, CEO of Quantum BioPharma.
Check This Out: <a href="https://www.benzinga.com/25/02/43461426/mercks-gardasil-vaccine-slowdown-in-china-bites-again-stock-falls-on-lower-than-expected-2025-outlook">Merck&#8217;s Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook</a>
Quantum BioPharma said the effects of unbuzzd occurred within 30 minutes after consumption of the dissolved powder. The company noted that unbuzzd was well-tolerated and safe, with no reported product-related adverse effects.
Quantum BioPharma is considered a low-float stock with just 1.83 million shares available for public trading, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The company also had a market cap of approximately $6 million as of Monday's close.&nbsp;Low-float, micro-cap stocks can be extremely volatile, which may be contributing to some of Tuesday's surge.
QNTM Price Action: <a href="http://benzinga.com/quote/qntm">Quantum BioPharma shares</a> were up 79.6% at $5.71 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

QNTM

Quantum BioPharma Stock Is Soaring Tuesday: What's Driving The Action?

PLCE and EFOI among Consumer Discretionary movers

Yunhong Green&nbsp; GAAP EPS of -$0.01, revenue of $6.8M

Yunhong Green CTI Ltd (YHGJ) Q4 2023 Earnings Call Transcript

Yunhong Green CTI receives non-compliance notification from Nasdaq

Yunhong Green Cti Ltd. ( ($YHGJ) ) has released its Q3 earnings. Here is a breakdown of the information Yunhong Green Cti Ltd. presented to its inv...

Comments

Yunhong Green CTI

Noticias

Últimas noticias sobre Yunhong Green CTI (NASDAQ:YHGJ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL